Core Viewpoint - Heng Rui Medicine (01276) has seen a stock price increase of over 4%, currently trading at 77.8 HKD, with a transaction volume of 103 million HKD, following the announcement of two innovative drugs receiving approval for clinical trials in prostate cancer treatment [1]. Group 1: Drug Approvals - Heng Rui Medicine announced that its two self-developed innovative drugs, HRS-4357 injection and HRS-5041 tablets, have been approved by the National Medical Products Administration for clinical trials targeting prostate-specific membrane antigen (PSMA) positive prostate cancer [1]. - HRS-4357 is a Class 1 radioactive therapeutic drug, and this approval represents an expansion based on its previous single-agent clinical trials [1]. - HRS-5041 is a novel androgen receptor protein degradation-targeting chimeric small molecule drug, designed to treat prostate cancer by degrading AR proteins, with potential to overcome resistance to existing therapies [1]. - The announcement highlighted that there are currently no similar products approved for market release domestically or internationally [1].